GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Avalyn Pharma Inc. Common Stock AVLN · USD

US listing · 🇺🇸 United States

Compare

29.50

+1.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$85.2m

FY2024FY2025

Free cash flow

−$81.8m

FY2024FY2025

Shareholders' equity

−$238.7m

FY2024FY2025

Income statement

Fiscal years

FY2025FY2024
Research and development$76.6m$45.8m
Operating income−$91.3m−$57.1m
Net income−$85.2m−$49.7m
Diluted earnings per share-2.04-1.19

Balance sheet

At each fiscal year end

FY2025FY2024
Total assets$148.9m$124.5m
Cash and short-term investments$138.4m—
Total liabilities$387.5m$299.0m
Debt$444,000—
Shareholders' equity−$238.7m−$174.5m
Shares outstanding42m42m

Cash flow

Fiscal years

FY2025FY2024
Cash from operations−$81.5m−$48.4m
Capital spending−$344,000−$95,000
Free cash flow−$81.8m−$48.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Mar 2025
Gross profit−$110,000——
Operating income−$31.3m−$27.9m−$18.7m
Net income−$28.9m−$26.9m−$17.5m
Diluted earnings per share-0.65-0.61-0.42
Cash from operations−$26.0m−$29.0m−$19.0m
Total assets$425.4m$135.7m—
Cash and short-term investments$352.4m$123.1m—
Debt$816,000$15.3m—
Shareholders' equity$398.3m−$264.2m—

Financial ratios

Data as of 4 Nov 2026

FY2025FY2024
Return on equity35.7%28.5%
Return on assets-57.2%-39.9%
Earnings growth71.3%—
Current ratio10.19x13.08x
Debt to equity-0.00x—
Equity ratio-160.3%-140.2%

Market value over time

30 Apr 2026 to 3 Nov 2026, in USD

$1.23bn$1.19bn

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.